BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9504632)

  • 1. Flow cytometric identification of candidate normal stem cell populations in CD45-negative B-cell precursor acute lymphoblastic leukaemia.
    Vormoor J; Baersch G; Baumann M; Ritter J; Jürgens H
    Br J Haematol; 1998 Mar; 100(3):501-8. PubMed ID: 9504632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia.
    Baersch G; Baumann M; Ritter J; Jürgens H; Vormoor J
    Br J Haematol; 1999 Dec; 107(3):572-80. PubMed ID: 10583262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Flow cytometric characterization of maturation processes and primitive stem cell population in pre-B-cell ALL in childhood].
    Baersch G; Baumann M; Meltzer J; Möllers T; Ritter J; Jürgens H; Vormoor J
    Klin Padiatr; 1996; 208(4):160-7. PubMed ID: 8926682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
    Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.
    Wilson K; Case M; Minto L; Bailey S; Bown N; Jesson J; Lawson S; Vormoor J; Irving J
    Haematologica; 2010 Apr; 95(4):679-83. PubMed ID: 19951974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology.
    Moon H; Huh J; Cho MS; Chi H; Chung WS
    Korean J Lab Med; 2007 Aug; 27(4):253-6. PubMed ID: 18094585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD34 on human B cell precursors.
    Schmitt C; Eaves CJ; Lansdorp PM
    Clin Exp Immunol; 1991 Jul; 85(1):168-73. PubMed ID: 1712682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
    Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
    Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
    Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
    Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
    Kim SM; Lee ST; Ryu KJ; Kim HJ; Kim SH; Ko YH; Kim WS; Kim SJ
    Leuk Lymphoma; 2015; 56(11):3052-7. PubMed ID: 25739938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference of bone marrow CD56
    Theodorakos I; Paterakis G; Papadakis V; Vicha A; Topakas G; Jencova P; Karchilaki E; Taparkou A; Tsagarakis NJ; Polychronopoulou S
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27799. PubMed ID: 31066205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
    Weir EG; Cowan K; LeBeau P; Borowitz MJ
    Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
    Kahng J; Shin SY; Han K
    Korean J Lab Med; 2007 Dec; 27(6):406-13. PubMed ID: 18160830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
    Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
    Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
    Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A flow cytometric assay of CD34-positive cell populations in the bone marrow.
    Syrjälä M; Ruutu T; Jansson SE
    Br J Haematol; 1994 Dec; 88(4):679-84. PubMed ID: 7529536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.